@article{59efa394be164f51979207e3d6dd5aef,
title = "Deciphering the factors that influence participation in studies requiring serial lumbar punctures",
abstract = "Introduction: Cerebrospinal fluid biomarkers increasingly inform the causes of dementia and may provide objective markers of disease progression. There is a need to decipher participant and procedural factors that promote participation in studies incorporating longitudinal biomarker measures. Methods: Participant and procedural factors associated with participation in longitudinal biomarker studies were determined in individuals enrolled in studies of memory and aging at the Knight Alzheimer Disease Research Center (Saint Louis, MO, USA). Results: Complications were encountered following 331 of 1484 lumbar punctures (22.3%; LPs), affecting 280 of 929 participants (30.1%); in >95% complications were minor. Three hundred fifteen of 679 eligible participants (46.4%) completed multiple LPs. Younger age (odds ratio [OR] 2.08 per decade [95% confidence interval (CI) 1.61–2.94]), normal cognition (OR 21.4 [2.85–160.1]), and the absence of heart disease (OR 2.0 [1.01–3.85]) or seizures at study entry identified participants with increased odds of completing three or more LPs. Discussion: Factors influencing participation may be leveraged to improve recruitment and retention within observational and therapeutic studies requiring serial LPs.",
keywords = "Alzheimer's disease, biomarker, cerebrospinal fluid, dementia, lumbar puncture",
author = "Day, {Gregory S.} and Tracy Rappai and Sushila Sathyan and Morris, {John C.}",
note = "Funding Information: Study funding was provided through National Institutes of Health grants P50AG005681, P01AG003991, and P01AG026276, with additional support from the Advanced Summer Program for Investigation and Research Education (ASPIRE, Washington University; Tracy Rappai). Gregory S. Day is supported by a mentored career development award (K23AG064029) and from philanthropic support of the BJHF Willman Scholar Fund. Gregory S. Day holds stock in ANI Pharmaceuticals, Inc.; serves as a topic editor on dementia for DynaMed Plus (EBSCO Industries, Inc.); and has provided record review and expert medical testimony on legal cases pertaining to management of Wernicke encephalopathy. Tracy Rappai has nothing to disclose. Sushila Sathyan has nothing to disclose. John C. Morris is funded by NIH grants P50AG005681, P01AG003991, P01AG026276, and UF1AG032438. Neither John C. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. G.S.D. participated in study design; acquisition and interpretation of data; statistical analysis; and drafting, revision, and finalization of the manuscript. T.R. participated in acquisition and interpretation of data, statistical analysis, and drafting of the manuscript. S.S. participated in acquisition of data, and revision and finalization of the manuscript. J.C.M. participated in acquisition and interpretation of data, and revision and finalization of the manuscript. Publisher Copyright: {\textcopyright} 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of the Alzheimer's Association.",
year = "2020",
month = jan,
doi = "10.1002/dad2.12003",
language = "English",
volume = "12",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
number = "1",
}